InfuSystem updates TTM revenue to ~$140M, adj EBITDA ~$30M; net leverage 0.86x

InfuSystem Holdings, Inc

TTM 6/30/25 net revenue ~$140M, up from $134.9M in FY2024; adjusted EBITDA ~$30M vs. $25.3M.
Net leverage 0.86x, debt/equity 0.85x, total available liquidity $49.1M.
Share repurchase: $7.6M bought under $20M program through June 30, 2025.
Patient Services gross margin 64.5% TTM; Device Solutions gross margin 39.6% TTM.
Management estimates FY2025 revenue growth 6-8% and adjusted EBITDA margin >20%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.